<DOC>
	<DOCNO>NCT00545571</DOCNO>
	<brief_summary>This single-arm study ass long-term maintenance hemoglobin level , safety , tolerability once-monthly intravenous administration Mircera hemodialysis participant chronic renal anemia . Those currently receive darbepoetin alfa , epoetin alfa , epoetin beta maintenance treatment receive intravenous Mircera start dose 120 , 200 , 360 microgram ( mcg ) per month ( base erythropoiesis stimulate agent [ ESA ] dose administer Week -1 ) . Subsequent dos adjust maintain hemoglobin level within country-specific target range ( 11 13 gram per deciliter [ g/dL ] Switzerland 10 12 g/dL Austria ) .</brief_summary>
	<brief_title>MIRACLE Study : A Study Once-Monthly Intravenous Mircera Hemodialysis Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adults great equal ( ≥ ) 18 year age Chronic renal anemia Hemoglobin concentration countryspecific target range ( Switzerland : 11 13 g/dL ; Austria : 10 12 g/dL ) Regular longterm hemodialysis therapy mode dialysis ≥3 month Continuous intravenous subcutaneous maintenance ESA treatment previous 2 month Transfusion red blood cell previous 2 month Significant acute chronic bleeding , overt gastrointestinal bleeding Active malignant disease ( except nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>